International Stem Cell Corporation (ISCO), a California-based biotechnology company developing novel stem cell-based therapies, has entered into a research agreement with Rohto Pharmaceutical Co., Ltd. (Rohto), a global Japanese pharmaceutical company that develops new technology for the medical and cosmetics markets with approximately $1.3 billion in consolidated annual sales. Under this agreement, Rohto will evaluate stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. If the research is successful and the parties agree on remaining terms, it is anticipated that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. Certain key terms of such a license agreement, including the target disease areas and intellectual property rights, have been established in the research agreement.
"We are delighted to have such an outstanding company work with us, and we believe that the potential for this agreement is significant," said Dr. Simon Craw, EVP of Business Development at ISCO. "Under the terms of the agreement Rohto will begin working with our cells immediately and if the program is successful we may move to the next stage, signing a definitive license agreement. Such an agreement would significantly enhance our standing in a number of ways. Firstly, having diligently built up our scientific strength and patent portfolio over the last few years, it would both validate our research as well as our ability to generate licensing revenue from our proprietary platform. Secondly, by expanding the use of our technology into new areas beyond that which we can address alone, it would add value to ISCO."
Under the agreement ISCO will provide a number of differentiated human cells derived from its collection of pluripotent human stem cells known as UniStemCell™. ISCO has a track record of successfully demonstrating that human cells derived from UniStemCell™ are effective in animal models of various diseases and have the potential to be used as a basis for developing human therapies.
Source: Marketwired News
Click here for the complete issue.